FeesSafety
Pluang+

Circle's Arc blockchain hits $494M TVL just 10 days after launch, showing rapid growth.

Protocol Fundamentals
26 Sep 2026, 12:03 WIB
Tokenpost
View Source
Bullish
Circle's Arc blockchain hits $494M TVL just 10 days after launch, showing rapid growth.

Circle's Arc blockchain achieved a total value locked (TVL) of $494 million in decentralized finance only 10 days after its mainnet launch, marking a significant early success. The TVL increased by 44.52% in the past week, the fastest growth rate among leading blockchains, indicating strong user adoption and activity. Additionally, decentralized exchange trading volume on Arc reached $55 million within 24 hours, further highlighting the network's growing traction. This rapid growth positions Arc as one of the fastest-growing blockchain networks in the DeFi space, suggesting promising potential for future development and investment.

Circle's Arc blockchain's rapid DeFi growth is notable, and for readers following cryptocurrency markets, here is Pluang's market snapshot as of Sep 26, 2026 16:01 WIB: Among 50 major cryptocurrencies tradable on Pluang, 35 rose and 14 fell today. Uniswap (UNI) rose 3.88% to Rp172.151 with a typical hold time of 65 days and 97% buy order activity, Theta Network (THETA) gained 3.54% to Rp4.120 with 87% buy orders, and Solana (SOL) increased 3.08% to Rp2.163.525 with 60% buy orders.

More News

Velinotamig shows strong safety and efficacy in treating refractory systemic lupus erythematosus, with notable kidney improvements.

Velinotamig shows strong safety and efficacy in treating refractory systemic lupus erythematosus, with notable kidney improvements.

Cullinan Therapeutics announced promising Phase 1b/2a trial results for velinotamig, a BCMAxCD3 T cell engager, in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE). Among nine evaluable patients, eight showed significant...

Market News
Bullish
2 hours ago
CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.

CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.

CRISPR Therapeutics announced encouraging Phase 1 trial results for zugo-cel, their gene-edited CAR-T cell therapy targeting refractory autoimmune diseases like systemic sclerosis, lupus, and idiopathic inflammatory myopathy. Among 21 patients treate...

Market News
Bullish
2 hours ago
Colin Kaepernick named Humanitarian of the Year at 2026 Muhammad Ali Humanitarian Awards.

Colin Kaepernick named Humanitarian of the Year at 2026 Muhammad Ali Humanitarian Awards.

At the 13th annual Muhammad Ali Humanitarian Awards in Louisville, Colin Kaepernick was honored as Humanitarian of the Year for his activism and entrepreneurship, including founding literacy platform Lumi and Know Your Rights Camp. The event also rec...

Others
Neutral
3 hours ago
New Phase 1/2 data show Cabaletta's rese-cel therapy offers durable, immunomodulator-free benefits in autoimmune diseases.

New Phase 1/2 data show Cabaletta's rese-cel therapy offers durable, immunomodulator-free benefits in autoimmune diseases.

Cabaletta Bio announced Phase 1/2 clinical data for rese-cel, a CAR T cell therapy targeting autoimmune diseases, showing durable benefits without immunomodulators across dermatomyositis, lupus nephritis, and systemic sclerosis patients. All dermatom...

Market News
Bullish
3 hours ago
Coinbase completes Aerodrome and Velodrome token upgrade, restores new AERO and VELO transfers.

Coinbase completes Aerodrome and Velodrome token upgrade, restores new AERO and VELO transfers.

Coinbase has finished converting Aerodrome Finance (AERO) and Velodrome Finance (VELO) tokens to a new Aero (AERO) token. The exchange has resumed send and receive functions for both AERO and VELO tokens. However, Coinbase no longer supports deposits...

Protocol Fundamentals
Neutral
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App